TamirBio develops therapeutics drugs intended to treat human viral diseases.

TamirBio’s initial clinical target is the treatment of HPV. Worldwide, there are 14 million new and recurrent infections caused by HPV (the most common sexually transmitted disease). Today‚Äôs therapeutic options all have shortcomings including high rates of recurrence, the need for continued application, or invasiveness. TamirBio asserts that clinicians and patients will adopt a topically applied option that demands only 1-2 applications with a high safety profile.

INDUSTRY

MILESTONES

Year founded: 1981

Arc investment: 2018

Acquired: 2020

FOUNDERS

ARC TEAM

LATEST TWEETS